Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects

Journal of Clinical Pharmacology

Volumn 41, Issue 5, 2001, Pages 573-581

  Prueksaritanont, T ^a   Vega, J M ^a   Zhao, J ^a   Gagliano, K ^a   Kuznetsova, O ^a   Musser, B ^a   Amin, R D ^a   Liu, L ^a   Roadcap, B A ^a   Dilzer, S ^a   Lasseter, K C ^a   Rogers, J D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; SIMVASTATIN; TROGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CHROMANS; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEADACHE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SIMVASTATIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 17744369675     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010311     Document Type: Article

References (32)

1. Mevinolin: A highly potent competitive inhibitor of hydroxy-methylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
2. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase
3. Metabolic disposition of simvastatin in patients with T-tube drainage
4. In vitro metabolism of simvastatin in humans: Identification of metabolizing enzymes and effect of the drug on hepatic P450s
5. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
6. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
7. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
8. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects
9. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus
10. New agents for type II diabetes
11. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders
12. Withdrawal of troglitazone and cisapride
13. Pharmacokinetics of troglitazone, an antidiabetic agent: Prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data
14. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites
15. Clinical pharmacokinetics of troglitazone
16. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
17. Effect of troglitazone on terfenadine pharmacokinetics
18. Potential interaction of troglitazone and cyclosporine
19. Effect of troglitazone on cyclosporine whole blood levels
20. Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent
21. Effect of troglitazone on urinary excretion of cortisol and 6β-hydroxycortisol
22. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
23. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin
24. Pharmacokinetics of troglitazone in healthy subjects and in patients with Type II diabetes mellitus
25. Clinical pharmacokinetics of pioglitazone
26. Effect of troglitazone on PK and PD of atorvastatin
27. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes
28. Troglitazone enhances midazolam metabolism
29. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics
30. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes